Aurisco Pharmaceutical Co Ltd (605116) — Cash Flow Quality Index
Aurisco Pharmaceutical Co Ltd (605116) has a Cash Flow Quality Index of 0.94x as of December 2024. Operating cash flow of CN¥332.41 Million is below net income of CN¥354.79 Million, suggesting accrual-heavy earnings not yet converted to cash. Explore Aurisco Pharmaceutical Co Ltd (605116) cash flow conversion to assess how effectively this company generates cash.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Aurisco Pharmaceutical Co Ltd Cash Flow Quality Index (2017–2024)
Historical Cash Flow Quality Index for Aurisco Pharmaceutical Co Ltd across 8 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check 605116 cash reinvestment to operating cash ratio to assess the company's total reinvestment commitment from operating cash flow.
Annual Cash Flow Quality Index for Aurisco Pharmaceutical Co Ltd (2017–2024)
Year-by-year earnings quality comparison for Aurisco Pharmaceutical Co Ltd. For live market cap and the full company financial profile, see Aurisco Pharmaceutical Co Ltd stock valuation.
| Year | Quality Index | Operating CF (CNY) | Net Income | YoY Change |
|---|---|---|---|---|
| 2024 | 0.94x | CN¥332.41 Million | CN¥354.79 Million | ▼ -29.7% |
| 2023 | 1.33x | CN¥385.61 Million | CN¥289.42 Million | ▲ +66.7% |
| 2022 | 0.80x | CN¥166.41 Million | CN¥208.21 Million | ▼ -33.3% |
| 2021 | 1.20x | CN¥201.57 Million | CN¥168.28 Million | ▼ -12.2% |
| 2020 | 1.36x | CN¥214.48 Million | CN¥157.23 Million | ▲ +41.1% |
| 2019 | 0.97x | CN¥179.90 Million | CN¥186.13 Million | ▲ +20.5% |
| 2018 | 0.80x | CN¥109.77 Million | CN¥136.83 Million | ▼ -69.6% |
| 2017 | 2.64x | CN¥117.91 Million | CN¥44.72 Million | — |